Staff Reports
The Biden administration and the FDA rolled out a so‑called “Green List” this past September as a response to a real problem — illegal and potentially dangerous GLP‑1 drug ingredients entering our market — but the rollout reads more like theater than security. The list was supposed to protect Americans by allowing only inspected and compliant foreign manufacturers to avoid automatic detention at the border, yet the policy’s effectiveness depends entirely on the agencies actually doing the work of inspection.
Senator Jim Banks has sounded the alarm for good reason, urging the FDA to ramp up on‑the‑ground inspections and calling out painfully low inspection rates at overseas facilities that supply our pharma supply chain. In a letter to FDA leadership, Banks noted that inspections in China and India covered only a fraction of registered sites, and he warned that the Green List is only as trustworthy as the agency’s willingness to inspect and re‑inspect these firms.
Make no mistake: the Green List comes with teeth on paper — Import Alert 66‑80 authorizes detention without physical examination for GLP‑1 APIs from any source not explicitly vetted — but that tool becomes meaningless if inspections are cursory or sporadic. The import alert framework can be powerful, yet the administration’s track record of resource‑starved oversight means Americans can’t just take its assurances at face value.
Industry watchdogs and FOIA‑obtained inspection records raise troubling questions about some foreign facilities that appear to have been green‑listed despite serious compliance concerns, including sanitation and documentation problems. Reports that elements like insect contamination and residue issues showed up in inspection findings should set off alarm bells; our citizens deserve more than press releases and opaque lists.
Experts tracking the peptide and API supply chain have documented that a mix of manufacturers across Canada, Denmark, India, and China were included among vetted sites — which shows the FDA can and did inspect some foreign producers, but also underlines the scale of oversight required. When a regulatory system depends on sporadic spot checks across dozens of facilities worldwide, the practical risk of substandard or untested drugs slipping through rises dramatically.
This isn’t a partisan quibble; it’s about life and death and the protection of American families from profit‑driven suppliers operating under thin oversight. Conservatives should demand more than cosmetic reforms: fund more unannounced inspections, publish clear and timely lists with verifiable evidence, and hold companies accountable with immediate enforcement — not bureaucratic delays that put patients at risk.
If Washington won’t act, Congress must use its power of the purse and of oversight to force accountability. Americans pay for a government that protects them; it’s time Republicans and sane Democrats alike stop the charade, prioritize domestic manufacturing, and make sure the drugs on our shelves are safe, tested, and produced under American standards. The people deserve nothing less.
